astrazeneca oral glp 1 Expands into Obesity with GLP-1 Therapy | Ahmad Hammoud, Pharmacist, One Health Professional posted on the topic AstraZeneca Advances Elecoglipron to Phase

GLP-1 medications may cause uncomfortable side effects and increase the risk of gastrointestinal conditions

Corner TP, Tumber A, Salah E, Jabbary M, Nakashima Y, Schnaubelt LI, Basak S, Alshref FM, Brewitz L, Schofield CJ (2025) Derivatives of the clinically used HIF prolyl hydroxylase inhibitor desidustat are efficient inhibitors of human -butyrobetaine hydroxylase

People who report difficulty filling their prescription are three times as likely to switch medications as those who do not

For research use, material backed by independent HPLC verification and a published batch Certificate of Analysis provides documented confidence in what is supplied

These are beneficial for tissue repair, but in a patient whose clotting cascade is already pharmacologically suppressed, enhanced vasodilation and new vessel formation may increase the risk of hemorrhage at injury sites

S., Dostert, C., Nonnenmacher, Y., Cox, M., Binsfeld, C., Hao, Z., Brstle, A., Itsumi, M., Jger, C., Chen, Y., Pinkenburg, O., Camara, B., Ollert, M., Bindslev-Jensen, C., Vasiliou, V., Gorrini, C., Lang, P